E. Autzinger

Tumor stabilization under treatment with imatinib in progressive hypothalamic‐chiasmatic glioma

D. Prayer, I. Slavc, T. Czech, 2009, Pediatric blood & cancer.

Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

L. Pleyer, R. Greil, P. Krippl, 2014 .

Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry

L. Pleyer, R. Greil, P. Krippl, 2014 .

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

L. Pleyer, R. Greil, P. Krippl, 2017, International journal of molecular sciences.

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

L. Pleyer, R. Greil, S. Machherndl-Spandl, 2016, Journal of Hematology & Oncology.

Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres.

W. Schima, J. Zacherl, U. Vogl, 2020, Journal of gastrointestinal oncology.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

R. Greil, R. Hájek, H. Gisslinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

L. Pleyer, R. Greil, H. Döhner, 2017, International journal of molecular sciences.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

R. Greil, H. Ludwig, A. Weissmann, 2015, Haematologica.

Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

L. Pleyer, R. Greil, S. Machherndl-Spandl, 2015 .

Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study.

R. Greil, R. Hájek, H. Gisslinger, 2009 .